MedTrace Logo

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets

NCT04853498 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2026-03-31

No results posted yet for this study

Summary

This study is conducted to investigate the pharmacokinetic and safety profiles of TQB3720 in patients with metastatic castration-resistant prostate cancer.

Conditions

Interventions

DRUG

TQB3720

This is an androgen receptor antagonists.

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-09
Primary Completion
2024-04-30
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04853498 on ClinicalTrials.gov